Recent Updates — GLAXF
GSK plc has announced the indicative provisional dividend schedule for its ordinary shares and American Depositary Shares (ADS) for the full year of 2027. The filing details specific ex-dividend, record, DRIP election, and payment dates for each quarter: Q1 payable July 15, 2027; Q2 payable October 14, 2027; Q3 payable January 13, 2028; and Q4 payable April 13, 2028. The company notes these dates are subject to change. GSK plc is a global healthcare company focused on vaccines, specialty medicines, and consumer health products.
GSK announced positive interim results from the phase II AZUR-1 trial evaluating Jemperli (dostarlimab) as a standalone treatment for stage II and III MSI-H/dMMR locally advanced rectal cancer. In an exploratory analysis, 76% of evaluable patients achieved a complete response to dostarlimab alone, with no disease recurrences reported among responders after a median follow-up exceeding two years. The data supports the drug's recent US approval in this indication and will be presented at the ESMO Congress. GSK is a global biopharmaceutical company focused on developing differentiated medicines for cancers and other diseases.
GSK announced updated data from the global phase I BEHOLD-1 trial for mocertatug rezetecan (Mo-Rez), an investigational B7-H4-targeted antibody-drug conjugate. Results showed a confirmed objective response rate of 62% and a median duration of response of 12.2 months in patients with platinum-resistant ovarian cancer. Median progression-free survival was 11.1 months, supporting the selected phase III dose of 5.8 mg/kg. Five pivotal phase III studies are now underway across gynaecological cancers. GSK is a global biopharmaceutical company focused on vaccines, generic medicines, and specialty pharmaceuticals.
The US FDA has approved Jemperli (dostarlimab) under the accelerated approval pathway as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) locally advanced rectal cancer. The approval is based on AZUR-1 trial data showing a 68% sustained clinical complete response rate at 12 months, with no disease recurrences reported among responders after more than two years of follow-up. This monotherapy offers eligible patients the potential to avoid chemotherapy, radiation, and surgery. GSK plc operates as a global biopharmaceutical company focused on vaccines, specialty medicines, and consumer healthcare.
GSK announced the first global data for its investigational antibody-drug conjugate, risvutatug rezetecan (Ris-Rez), in patients with relapsed extensive-stage small cell lung cancer. Results from the dose-optimization portion of the EMBOLD PanTumour-101 trial showed a confirmed objective response rate of 61% at an 8 mg/kg dose, compared to 32% at 6 mg/kg. The safety profile was manageable, with Grade 3 or higher treatment-related adverse events observed in 42% of patients receiving the higher dose. These findings support the selection of the 8 mg/kg dose for ongoing global phase III trials and build on positive pivotal data previously reported in Chinese patients. GSK is a global biopharmaceutical company focused on vaccines, generics, and specialty medicines.